0001104659-24-067356.txt : 20240531 0001104659-24-067356.hdr.sgml : 20240531 20240531213600 ACCESSION NUMBER: 0001104659-24-067356 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240530 FILED AS OF DATE: 20240531 DATE AS OF CHANGE: 20240531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kruse Bo CENTRAL INDEX KEY: 0001752940 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38650 FILM NUMBER: 241011799 MAIL ADDRESS: STREET 1: C/O Y-MABS THERAPEUTICS, INC. STREET 2: 230 PARK AVENUE, 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc. CENTRAL INDEX KEY: 0001722964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474619612 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 212-847-9841 MAIL ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 4 1 tm2416233-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-05-30 0 0001722964 Y-mAbs Therapeutics, Inc. YMAB 0001752940 Kruse Bo C/O Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE, SUITE 3350 NEW YORK NY 10169 0 1 0 0 EVP, CFO, SECRY & TREAS. 0 Common Stock 2024-05-30 4 M 0 28629 2.00 A 239506 D Common Stock 2024-05-30 4 S 0 28629 12.03 D 210877 D Common Stock 2024-05-31 4 M 0 31371 2.00 A 242248 D Common Stock 2024-05-31 4 S 0 31371 12.07 D 210877 D Employee Stock Option (right to buy) 2.00 2024-05-30 4 M 0 28629 0 D 2025-06-10 Common Stock 28629 271371 D Employee Stock Option (right to buy) 2.00 2024-05-31 4 M 0 31371 0 D 2025-06-10 Common Stock 31371 240000 D This transaction was executed in multiple trades at prices ranging from $11.85 to $12.22, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $11.87 to $12.42, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. All of these stock options are currently vested. /s/ John LaRocca, Attorney-in-Fact 2024-05-31